ArticleCancer cell2012
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 137 citations in OpenAlex.
- Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.British journal of haematology · 2017Trial
- IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.Blood · 2014Trial
- Trial
- Article
- A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies.Journal of hematology & oncology · 2026Article
- Debio 1562M CD37-targeting ADC is highly active and well tolerated in preclinical models of AML and MDS.Cell reports. Medicine · 2026Article
- Targeting CD37 promotes macrophage-dependent phagocytosis of multiple cancer cell types and facilitates tumor clearance in mice.Nature communications · 2025Article
- CD37 regulates the self-renewal of leukemic stem cells via integrin-mediated signaling in acute myeloid leukemia.Stem cell reports · 2025Article
- Theranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy.Cancers · 2025Review
- Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies.Cancer cell international · 2025Review
- CD37 in acute myeloid leukemia: a novel surface target for drug delivery.Blood advances · 2025Article
- The co-receptor Tetraspanin12 directly captures Norrin to promote ligand-specific β-catenin signaling.eLife · 2025Article
- PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.Blood advances · 2024Article
- The co-receptor Tetraspanin12 directly captures Norrin to promote ligand-specific β-catenin signaling.bioRxiv : the preprint server for biology · 2024Article
- N-Glycosylation-dependent regulation of immune-specific tetraspanins CD37 and CD53.Biophysical journal · 2024Article
- CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia.Cell reports. Medicine · 2024Article
- Tetraspanins: structure, dynamics, and principles of partner-protein recognition.Trends in cell biology · 2024Review
- Proximity-Based Labeling Identifies MHC Class II and CD37 as B Cell Receptor-Proximal Proteins with Immunological Functions.ImmunoHorizons · 2024Article
- Tetraspanins set the stage for bone marrow microenvironment-induced chemoprotection in hematologic malignancies.Blood advances · 2023Review
- Glioblastoma cell-derived exosomes induce cell death and oxidative stress in primary cultures of olfactory neurons. Role of redox stress.Molecular biology reports · 2023Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
29 authors at 4 institutions in 1 country.
Rosa LapalombellaDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Yuh-Ying YehDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Liwen WangDepartment of Chemistry, The Ohio State University, Columbus, OH 43210, USA.
Asha RamanunniDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Sarwish RafiqDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; The Integrated Biomedical Research Graduate Program, The Ohio State University, Columbus, OH 43210, USA.
Shruti JhaDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Justin StaubliDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; The Integrated Biomedical Research Graduate Program, The Ohio State University, Columbus, OH 43210, USA.
David M LucasDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
Rajeswaran ManiDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210, USA.
Sarah E M HermanDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; The Integrated Biomedical Research Graduate Program, The Ohio State University, Columbus, OH 43210, USA.
Amy J JohnsonDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
Arletta LozanskiDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Leslie AndritsosDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Jeffrey JonesDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Joseph M FlynnDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Brian LannuttiGilead Pharmaceuticals Inc, Seattle, WA 98102, USA.
Peter ThompsonOrbiMed Advisors, LLC, New York, NY 10017, USA.
Paul AlgateEmergent BioSolutions, Seattle, WA 98121-3460, USA.
Scott StromattEmergent BioSolutions, Seattle, WA 98121-3460, USA.
David JarjouraCenter for Biostatistics, The Ohio State University, Columbus, OH 43210, USA.
Xiaokui MoCenter for Biostatistics, The Ohio State University, Columbus, OH 43210, USA.
Dasheng WangDivision of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
Ching-Shih ChenDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
Gerard LozanskiDepartment of Pathology, The Ohio State University, Columbus, OH 43210, USA.
Nyla A HeeremaDepartment of Pathology, The Ohio State University, Columbus, OH 43210, USA.
Susheela TridandapaniDivision of Pulmonary Medicine, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Michael A FreitasDepartment of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA.
Natarajan MuthusamyDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210, USA; Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA. Electronic address: raj.muthusamy@osumc.edu.
John C ByrdDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210, USA; Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA. Electronic address: john.byrd@osumc.edu.
The Ohio State University · USEmergent BioSolutions (United States) · USGilead Sciences (United States) · USHealthcentric Advisors · US
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MTissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WIERDA, WILLIAM GEORGE · 2000 to 2016
$59.5MTWO SIGNAL REQUIREMENT FOR NATURAL KILLER IMMUNITYP01CA095426 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A · 2002 to 2016
$29.6MTranslational Training Grant in Experimental TherapeuticsK12CA133250 · NCI · OHIO STATE UNIVERSITY · PI WILLIAM E. CARSON, Rosa Lapalombella · 2008 to 2026
$15.0MPathologyP01CA101956 · NCI · OHIO STATE UNIVERSITY · PI BYRD, JOHN C. · 2006 to 2010
$11.4MSPORE Leukemia Tissue BankP50CA140158 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D · 2009 to 2013
$11.2MAssays for Screening Histone Modifications in CancerR01CA107106 · NCI · OHIO STATE UNIVERSITY · PI FREITAS, MICHAEL A. · 2004 to 2013
$1.8MNovel Immunotherapies for Lymphoid MalignanciesR01CA159296 · NCI · OHIO STATE UNIVERSITY · PI BYRD, JOHN C., MUTHUSAMY, NATARAJAN · 2012 to 2016
$1.6MNCI NIH HHS 1K12 CA133250NCI NIH HHS K12 CA133250NCI NIH HHS P01 CA081534NCI NIH HHS P01 CA095426NCI NIH HHS P01 CA101956NCI NIH HHS P01 CA81534NCI NIH HHS P01 CA95426NCI NIH HHS P30 CA016058NCI NIH HHS P50 CA140158NCI NIH HHS R01 CA107106NCI NIH HHS R01 CA159296
Abstract
Tetraspanins are commonly believed to act only as "molecular facilitators," with no direct role in signal transduction. We herein demonstrate that upon ligation, CD37, a tetraspanin molecule expressed on mature normal and transformed B cells, becomes tyrosine phosphorylated, associates with proximal signaling molecules, and initiates a cascade of events leading to apoptosis. Moreover, we have identified two tyrosine residues with opposing regulatory functions: one lies in the N-terminal domain of CD37 in a predicted "ITIM-like" motif and mediates SHP1-dependent death, whereas the second lies in a predicted "ITAM motif" in the C-terminal domain of CD37 and counteracts death signals by mediating phosphatidylinositol 3-kinase-dependent survival.
Indexed as
ApoptosisSignal TransductionAmino Acid MotifsAmino Acid SequenceAntigens, NeoplasmApoptosis Regulatory ProteinsBcl-2-Like Protein 11B-LymphocytesCell Line, TumorCell SurvivalChromatography, LiquidForkhead Box Protein O3Forkhead Transcription FactorsHEK293 CellsHumansImmunoglobulin GAntigens, NeoplasmApoptosis Regulatory ProteinsBCL2L11 protein, humanBcl-2-Like Protein 11CD37 protein, humanForkhead Box Protein O3Forkhead Transcription FactorsFOXO3 protein, humanImmunoglobulin GMembrane ProteinsPhosphatidylinositol 3-KinaseProto-Oncogene ProteinsRecombinant Fusion ProteinsTetraspaninsTRU 016Tyrosine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.